Fig. 6

Effect of long-term (10 weeks) empagliflozin treatment on cardiomyocyte minimal Feret’s diameter (a), cardiac interstitial fibrosis (b), cardiac DHE fluorescence (c), cardiac ED-1-positive cell numbers (d), and cardiac triglyceride contents (e) of SHRcp. Control SHRcp fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not significant. Values are mean ± SEM n = 12 in control, n = 12 in SGLT2. Statistical analysis was performed by unpaired Student’s t test